Skip to content Skip to footer
Subscribe Now

INSIGHTS+

New Drug Designations - April 2024
New Drug Designations – April 2024
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 11 small molecules, 7 biologics, 7 cell & gene therapies, 1 antiviral, 1 peptide and 3 devices   Lisata Therapeutics’ LSTA1 received ODD this month and was granted with…
May 30, 2024
Know Your Investor (May Edition) Alexandria Venture Investment
Know Your Investor (May Edition): Alexandria Venture Investment
Shots: In the May Edition of the Know Your Investor series, we are focussing on Alexandria Venture Investments, an integral part of Alexandria Real Estate Equities In 2023, Alexandria Venture Investments invested in 24 companies; 5, 8, 5 & 6 every quarter across 2023 respectively For a detailed report on all the investments, reach out…
May 28, 2024
Insights+ EMA Marketing Authorization of New Drugs in April 2024
Insights+: EMA Marketing Authorization of New Drugs in April 2024
Shots:   The EC approved 10 New Chemical Entities in April 2024, leading to treatments for patients and advances in the healthcare industry   In April 2024, the major highlighted drugs were Takeda’s Fruzaqla to treat Adults with mCRC and Johnson & Johnson’s Rybrevant for the treatment NSCLC  PharmaShots has compiled a list of 5 drugs that have received positive…
May 21, 2024
Disease of the Month – Sjögren’s Syndrome
Disease of the Month – Sjögren’s Syndrome
Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024
Insights+ The US FDA New Drug Approvals in April 2024
Insights+: The US FDA New Drug Approvals in April 2024
Shots:   PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2024   The US FDA approved a total of 12 new drugs including 11 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry     The major highlighted drug was X4 Pharmaceuticals’ Xolremdi for…
May 14, 2024
Insights+ Key Biosimilars Events of April 2024
Insights+ Key Biosimilars Events of April 2024
Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During April, Samsung Bioepis and Sandoz received the EC’s Marketing Authorization approval for Pyzchiva.…
May 2, 2024
New Drug Designations - March 2024
New Drug Designations – March 2024
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, MHRA and EC. This month’s report includes designations allotted to 10 small molecules, 6 biologics, 5 cell & gene therapy, 1 recombinant fusion protein, 2 actineoplastics, 1 antidepressant, 1 drug conjugate, 1 analgesic and 6 devices    Trellis Bioscience's…
April 30, 2024
Know Your Investor (April Edition) OrbiMed Advisors
Know Your Investor (April Edition): OrbiMed Advisors
Shots: An American investment firm, OrbiMed Advisor is a prominent name when it comes to healthcare investments. The company boasts a robust portfolio of more than 180 companies, including AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies, among others In 2023, OrbiMed invested in 38 funding rounds; 11, 6, 9 & 12 every quarter across 2023…
April 24, 2024
Insights+ EMA Marketing Authorization of New Drugs in March 2024
Insights+: EMA Marketing Authorization of New Drugs in March 2024
Shots:  The EC approved 1 Biologic and 11 New Chemical Entities in March 2024, leading to treatments for patients and advances in the healthcare industry  In March 2024, the major highlighted drugs were Novartis’ Fabhalta to treat PNH and UCB’s Bimzelx for the treatment of Adults with Moderate to Severe Hidradenitis Suppurativa  PharmaShots has compiled…
April 22, 2024
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]